FINAL STATEMENT OF REASONS
TITLE 27, CALIFORNIA CODE OF REGULATIONS

SECTION 25705(b) SPECIFIC REGULATORY LEVELS
POsing NO SIGNIFICANT RISK

NO SIGNIFICANT RISK LEVEL: GLYPHOSATE

This is the Final Statement of Reasons for the adoption of a No Significant Risk Level (NSRL)\(^1\) for glyphosate. On June 26, 2017, the Office of Environmental Health Hazard Assessment (OEHHA) announced the listing of glyphosate, effective July 7, 2017, as a chemical known to the state to cause cancer for purposes of Proposition 65\(^2\). OEHHA issued a Notice of Proposed Rulemaking to adopt a proposed amendment to Section 25705, Specific Regulatory Levels Posing No Significant Risk, identifying an NSRL of 1100 micrograms per day (μg/day) for glyphosate under Title 27, California Code of Regulations, section 25705(b)\(^3\). The Initial Statement of Reasons sets forth the grounds for the amendment to the regulation.

Briefly, in developing the NSRL for glyphosate, OEHHA relied on Volume 112 in the series of International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, entitled “Some Organophosphate Insecticides and Herbicides: Diazinon, Glyphosate, Malathion, Parathion, and Tetrachlorvinphos”\(^4\), which summarizes the available data from rodent carcinogenicity studies of glyphosate, as well as other information relevant to the carcinogenic activity of this chemical. The NSRL is based upon the results of the most sensitive scientific study deemed to be of sufficient quality\(^5\). OEHHA agrees with IARC’s determination that the increased incidence of hemangiosarcomas observed in a study of male CD-1 mice is treatment-related and is using that study as the basis for the NSRL.

---

\(^1\) No Significant Risk Levels (NSRLs) for cancer-causing chemicals have been established for many of the chemicals listed under Proposition 65. A business would not be required to provide a Proposition 65 warning for an exposure to a listed carcinogen that is at or below the NSRL.

\(^2\) The Safe Drinking Water and Toxic Enforcement Act of 1986, codified at Health and Safety Code section 25249.5 et. seq., hereafter referred to as “Proposition 65” or “The Act”.

\(^3\) All further regulatory references are to sections of Title 27 of the Cal. Code of Regs., unless otherwise indicated.


\(^5\) Section 25703(a)(4)
The Notice of Proposed Rulemaking was published in the California Regulatory Notice Register on April 7, 2017 (Register 2017, No. 14-Z) and initiated a 45-day public comment period that was scheduled to close on May 22, 2017. OEHHA received several requests to extend the public comment period and it was extended until June 21, 2017. OEHHA received over 1,300 oral and written public comments on the proposed rulemaking from several organizations and numerous individuals.

PEER REVIEW

As required by Section 25302(e) of the regulations, on May 17, 2017, OEHHA provided the notice of proposed rulemaking and the initial statement of reasons for the proposed NSRL for glyphosate to the members of the Carcinogen Identification Committee for their individual review and comment. OEHHA received peer-review comments from committee members Thomas McDonald, M.P.H., Ph.D., Luoping Zhang, PhD, Shanaz Dairkee, PhD, and Jason Bush, Ph.D.

UPDATED INFORMATION

There are no updates to the information contained in the ISOR, and no new documents were relied upon or added to the rulemaking file. Non-substantive revisions were made to the final regulation text to align the text with the text currently printed in the California Code of Regulations.

SUMMARY AND RESPONSE TO RELEVANT COMMENTS RECEIVED

OEHHA’s responses to the oral and written comments received throughout this rulemaking process are incorporated in this Final Statement of Reasons (FSOR). Some commenters analyzed IARC’s scientific conclusions, supporting or disagreeing with IARC’s classification of glyphosate as a Group 2A carcinogen and providing their own scientific analyses and conclusions, cited the conclusions of other international regulatory or scientific bodies that were contrary to IARC’s, or expressed or reiterated general disagreement with the addition of glyphosate to the Proposition 65 list; such comments are not directed to the subject of this rulemaking, which is the establishment of an NSRL for glyphosate. OEHHA responded to these types of comments in the listing documents for glyphosate and does not respond to them again here.

Other commenters discussed the US Environmental Protection Agency’s (US EPA’s) report entitled ‘Glyphosate Issue Paper: Evaluation of Carcinogenic Potential’6,

critiquing the analysis and conclusions therein, including comments that US EPA did not follow good laboratory practices in its weight of the evidence evaluation by omitting relevant studies\(^7\), as well as concerns that the cancer-related data provided by the US EPA has been brought into question based on allegations of collusion with Monsanto. These comments are not directed to the subject of this rulemaking and are not responded to here.

OEHHA additionally received many comments during the regulatory process that included observations or opinions regarding the use of glyphosate; suggestions that OEHHA conduct further studies into the health effects of glyphosate; statements that the NSRL does not consider impacts other than carcinogenicity; concerns of increased chronic illness among children and the lack of studies of the effects of pesticides on children\(^8\); opinions that glyphosate is safe, regulated, and effective; statements of support for other actions that are not the subject of this rulemaking (such as banning or restricting use of the chemical); and recommendations to use methods of clinical testing of 0.5 parts per billion or lower, and much lower for urine and water testing\(^9\). Some commenters expressed concern over the negative effects of genetically modified organisms (GMOs), that all GMOs should be banned, or that the US Food and Drug Administration should adopt mandatory regulations concerning genetically engineered plants and animals\(^{10}\). Some commenters also stated that Monsanto is greedy, corrupt, or withholding scientific evidence of glyphosate’s toxicity to humans and animals\(^{11}\). Such remarks do not constitute an objection or recommendation specifically directed at the proposed action, or the procedures followed in this rulemaking action. Accordingly, OEHHA is not required under the Administrative Procedure Act to respond to such comments in this FSOR. Because OEHHA is constrained by limitations upon its time and resources, and is not obligated by law to respond to irrelevant comments\(^{12}\), OEHHA does not provide responses to all of these remarks in this FSOR. However, the absence of responses to such remarks should not be construed to mean that OEHHA agrees with them.

Many commenters made the same or similar comments, and this document does not provide an exhaustive accounting of all commenters addressing the same point. A summary of the comments relevant to this rulemaking is provided below, along with OEHHA’s responses to those comments. As explained in detail in the responses to comments, OEHHA declines to change the proposed NSRL based on the comments.

---

\(^7\) Comment from Kurt Wallace.  
\(^8\) Comment from Michelle Perro  
\(^9\) Comment from Diane Rude  
\(^{10}\) Comment from Stephanie Easton  
\(^{11}\) Comment from Kathleen Furey  
\(^{12}\) California Government Code section 11346.9(a)(3)
Comment 1 (Baum, Hedlund, Aristei & Goldman, P.C., A Voice for Choice, Donna R. Farmer, Ph.D., on behalf of Monsanto and others): The potency estimate for the NSRL should be based on cancer findings from human epidemiological studies, rather than on findings from animal carcinogenicity studies. Many commenters assert that in failing to consider epidemiologic studies, the proposed safe harbor level does not conform to “quantitative risk assessment” and that OEHHA did not follow Section 25703 of the regulations.

Some of these commenters went on to state that prioritizing animal bioassays over epidemiological data overlooks the risk to individuals exposed to glyphosate during its application as a pesticide. They further argue that use of epidemiological data would provide a more robust and comprehensive evaluation of a chemical which most users absorb via cutaneous and respirational contact.

Paul Eusey, Tricia Brooks, and several other commenters stated that OEHHA should review the lowest levels of glyphosate in the epidemiological studies, but should always err on the side of caution and public health (see also Response #29 and discussion of precautionary principle).

Response 1: As stated in Section 25703 of the regulations, the assessment used to derive the NSRL “shall be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”\(^\text{13}\). Glyphosate was listed pursuant to the Labor Code listing mechanism\(^\text{14}\) as a result of IARC’s classification of glyphosate in Group 2A (“probably carcinogenic to humans”), with a finding of sufficient evidence of carcinogenicity in experimental animals\(^\text{15,16}\). IARC also found “there is limited evidence in humans for the carcinogenicity of glyphosate”, noting “[a] positive association has been observed for non-Hodgkin lymphoma.” Given that the listing of glyphosate is based on findings of limited evidence in humans and sufficient evidence in animals, basing the potency estimate for the NSRL on animal studies is both appropriate and consistent with Section 25703.

Animal bioassays are more frequently used than epidemiological data in quantitatively assessing the health risks of chemicals, including carcinogens. The epidemiological

\(^{13}\) Section 25703(a)(4)
\(^{14}\) Section 25249.8(a) of the Act
\(^{16}\) IARC (2015). Full citation provided in footnote 3.
studies evaluated by IARC, like many human studies, do not provide the type of information on levels of exposure that is needed for dose-response analysis. Specifically, these studies broadly characterized glyphosate exposure to individuals as either ‘never’ or ‘ever’ exposed, or as ‘duration’ of exposure, and were unable to quantify the individuals’ specific levels of exposure to the chemical. Since the epidemiology studies did not measure or estimate the dose level to which participants were exposed, a cancer potency cannot be calculated using these studies.

OEHHA disagrees with the commenters’ assertions that the use of animal cancer bioassay data to estimate cancer potency results in a less robust or comprehensive risk assessment than would the use of epidemiologic data, or that the use of animal data in some way overlooks risks to workers or other individuals exposed to glyphosate. As noted above, the epidemiologic studies available to date on glyphosate only provide limited evidence of a causal relationship between exposure and cancer risk, and they do not provide the type of information on levels of exposure needed in order to estimate cancer potency. Thus, OEHHA’s use of animal cancer bioassay data from the most sensitive study of sufficient quality to estimate human cancer potency for this chemical is appropriate and consistent with the Proposition 65 regulations17, other cancer risk assessment guidance from OEHHA18, and guidance from US EPA19. The estimate of human cancer potency is equally valid for estimating risks to occupationally exposed workers and to other individuals exposed to glyphosate, and the NSRL for glyphosate is not limited to a specific route of exposure20,21. No change to the regulatory proposal was made based on these comments.

Comment 2 (Moms Across America, Marty Eustis, Majorie Golden, Gloria Anderson and other commenters): Glyphosate induces breast cancer in humans. Marty Eustis commented that the NSRL should be “substantially lower” than the proposed 1100 micrograms/day in order to actually be safe to Californians. Majorie Golden, Gloria Anderson, and Marty Eustis commented that until a comprehensive independent study is done, the NSRL should be at or “well below 0.0001 mg/day” (Thongprakisang et al.), the concentration where it stimulated breast cancer cells in vitro.

17 Section 25703
21 Section 25703(a)(4)
Response 2: These comments all appear to be based on an *in vitro* study by Thongprakaisang et al. (2013)\textsuperscript{22}, in which glyphosate was shown to induce proliferation in a hormone-dependent human breast cancer cell line (T47D cells derived from ductal carcinoma cells), but not in a hormone-independent human breast cancer cell line (MDA-MB231 breast adenocarcinoma cells). This study is not a human epidemiology study and thus it does not provide evidence that glyphosate induces breast cancer in humans. Rather, it is a study of the effect of glyphosate on the proliferation of cultured cells, and it does not provide information that can be used to derive the NSRL for glyphosate. No changes were made to the regulatory proposal based on this comment.

Comment 3 (Monsanto, Ramboll Environ on behalf of The Scotts Company LLC, and others): Reviews by others have concluded that there are no treatment-related tumors in animal cancer bioassays of glyphosate, nor are there other datasets that provide evidence of a strong dose-response relationship of carcinogenicity that could be relied upon to estimate the potential for health effects in humans following exposure to expected concentrations and that the lack of an adequate dataset is consistent with conclusions reached by JMPR (2006) and US EPA (2016) that any tumor findings are not treatment-related. OEHHA has no basis to quantify an NSRL using experimental animal studies.

Response 3: Glyphosate was listed under Proposition 65 via the “Labor Code” listing mechanism, based on IARC’s classification\textsuperscript{23} of glyphosate as *probably carcinogenic to humans* (Group 2A), and its conclusion that there is *sufficient evidence* of carcinogenicity in experimental animals for glyphosate. IARC’s conclusion of sufficient evidence in experimental animals is based on findings from two studies in male mice. Specifically, IARC cited “a significant positive trend in the incidence of haemangiosarcoma [a malignant neoplasm] in male CD-1 mice” in a two-year diet study\textsuperscript{24}, and “a positive trend in the incidence of renal tubule carcinoma [a malignant neoplasm] and of renal tubule adenoma and carcinoma (combined) [an appropriate combination of benign and malignant neoplasms]” in male CD-1 mice in a different


\textsuperscript{23} IARC (2015). Full citation provided in footnote 3.

\textsuperscript{24} As noted in the Initial Statement of Reasons, this study of glyphosate (purity 98.6\%) met the criterion in Section 25703 as the most sensitive study of sufficient quality, and was used to derive the NSRL. This study was performed by Inveresk Research International and summarized in the 2006 Joint FAO/WHO Meeting on Pesticide Residues report (JMPR, 2006. Glyphosate. In: Joint FAO/WHO Meeting on Pesticide Residues. Pesticide residues in food — 2004: toxicological evaluations. Report No. WHO/PCS/06.1. Geneva: World Health Organization; pp. 95 – 169.) and by IARC (IARC, 2015, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 112. Some Organophosphate Insecticides and Herbicides: Diazinon, Glyphosate, Malathion, Parathion, and Tetrachlorvinphos. IARC, World Health Organization, Lyon, France).
two-year diet study\textsuperscript{25}, with IARC noting that these malignant kidney tumors are rare in this strain of mice. OEHHA agrees with IARC’s determination that these tumor findings are treatment-related and demonstrate statistically significant dose-response relationships.

In developing the NSRL for glyphosate, OEHHA followed the guidance set forth in Section 25703 that the assessment “be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”, and based the NSRL on the results of the most sensitive scientific study deemed to be of sufficient quality. OEHHA determined that the two-year study conducted in male CD-1 mice fed glyphosate (purity 98.6\%) in the diet, in which a significant positive trend in the incidence of hemangiosarcomas was observed, met the criteria in 25703 as the most sensitive study of sufficient quality. OEHHA used this data to derive the NSRL for glyphosate. No changes were made to the regulatory proposal based on this comment.

Comment 4 (Monsanto): The commenter cited the decision in \textit{Baxter Healthcare Corp. v. Denton}, 120 Cal. App. 4\textsuperscript{th} 333, 15 Cal. Rptr. 3d 430 (2004) to support its assertion that OEHHA is required to determine that a glyphosate exposure at any level does not pose a “significant risk”, and as such requires OEHHA to establish an “infinite” NSRL. Baum, Hedlund, Aristei & Goldman, P.C. and others stated that Monsanto’s reliance on \textit{Baxter v. Denton} is inappropriate.

Response 4: OEHHA disagrees that the \textit{Baxter} decision mandates the establishment of an infinite NSRL. The decision in \textit{Baxter} is factually distinguishable from the proposed NSRL for glyphosate\textsuperscript{26}. The commenter provides no evidence that the mechanism of action for glyphosate does not operate in humans, which was the pivotal issue in that case. In \textit{Baxter}, the Appellate Court focused on evidence that the mechanism by which DEHP increased the incidence of liver tumors in animals was not relevant to humans\textsuperscript{27}. This notably included evidence regarding the classification of DEHP by IARC\textsuperscript{28}. At the time of the \textit{Baxter} decision, IARC had downgraded its earlier classification of DEHP as Group 2B (“possibly carcinogenic to humans”) to Group 3 (“not classifiable as to its carcinogenicity to humans”). Glyphosate, on the other hand,

---


\textsuperscript{26} See comment letters from Baum, Hedlund, Aristei & Goldman, P.C., (Comment #9945) and Center for Biological Diversity, et al. (Comment #9974)]

\textsuperscript{27} \textit{Baxter Healthcare Corp. v. Denton}, 120 Cal. App. 4\textsuperscript{th} 333, 15 Cal. Rptr. 3d 430 (2004), at 438.

\textsuperscript{28} \textit{Id.}
has received a higher Group 2A classification from IARC\textsuperscript{29}. IARC’s Group 2A classification of glyphosate is based on “sufficient evidence” in animal studies and “limited evidence” in human (epidemiological) studies. IARC found that mechanistic and other relevant data support the Group 2A classification of glyphosate (e.g., “strong” evidence for genotoxicity, both for “pure” glyphosate and for glyphosate formulations) and concluded, “[t]here is evidence that these effects can operate in humans”. IARC has not reclassified glyphosate, or modified its findings that animal studies provided sufficient evidence of carcinogenicity and human studies provided limited evidence of carcinogenicity. No changes to the regulatory proposal were made based on this comment.

Comment 5 (Monsanto, Chris Portier, SafeAgSafeSchools, Anthony Samsel, Baum, Hedlund, Aristei & Goldman, P.C., and others): Monsanto commented that according to Section 25703, OEHHA’s assessment is not limited to the specific studies used as the basis for listing the chemical, but instead OEHHA’s “assessment shall be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for listing the chemical as known to the state to cause cancer.” Monsanto went on to say that OEHHA’s basis for listing is IARC’s classification of glyphosate as a category 2A chemical on the basis of sufficient evidence in animals and that OEHHA should consider all available rodent studies and not just the select few that IARC chose to evaluate. The other studies contradict the conclusions reached by IARC’s working group with respect to the four referenced animal studies.

Additionally, Chris Portier, Safe Ag Safe Schools, Anthony Samsel, Baum, Hedlund, Aristei & Goldman, P.C., Sonoma County Conservation Action\textsuperscript{30} and others requested that OEHHA analyze and incorporate additional bioassay data in the derivation of an NSRL for glyphosate, not just studies reviewed by IARC. This includes the studies discussed in the review article by Greim et al. (2015). Some of these studies, including Wood et al. (2009), Lankas (1981), and Stout and Ruecker (1990), as cited by Baum, Hedlund, Aristei & Goldman, P.C. and Safe Ag Safe Schools, observed tumors or lymphomas at much lower doses than the study used to derive the NSRL. Baum, Hedlund, Aristei & Goldman, P.C, stated that if the data from these studies were used, a significantly lower NSRL would have been reached. Safe Ag Safe Schools stated that the NSRL is not based on the most sensitive study of acceptable quality and should be based on a dose of 31.49 mg/kg/day. Chris Portier and the Center for Biological Diversity commented that the Atkinson study is not the most sensitive study of sufficient

\textsuperscript{29} IARC (2015). Full citation provided in footnote 3.
\textsuperscript{30} The commenter suggested a revised NSRL based on a dose of 31.39/mg/kg/day, which is related to the Lankas study discussed in Greim et al.
quality to guide the suggested NSRL, and that other studies provide a more scientifically sound and health-protective basis for calculating the NSRL (i.e., Wood et al. [2009], Lankas [1981], and Stout and Ruecker [1990]), and that OEHHA must do an independent analysis of these studies and not rely on US EPA’s conclusions.

During the public hearing for this rulemaking, Dr. Donna Farmer, senior toxicologist at Monsanto’s Regulatory Product Safety Center, commented that OEHHA’s reliance on male mouse hemangiosarcomas is not justified for the derivation of a NSRL.

Seosamh Devine commented that OEHHA relied too much on Monsanto’s scientific opinions.

Response 5: As noted by the commenters, Section 25703 of the regulations states that the assessment used to derive the cancer potency “shall be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”31. Glyphosate was listed under Proposition 65 via the “Labor Code” listing mechanism, based on IARC’s classification32 of glyphosate as probably carcinogenic to humans (Group 2A), and its conclusion that there is sufficient evidence of carcinogenicity in experimental animals for glyphosate. As discussed in response to comment 3, IARC’s conclusion of sufficient evidence in experimental animals is based on findings from two studies in male mice. Specifically, IARC cited “a significant positive trend in the incidence of haemangiosarcoma in male CD-1 mice” in a two-year diet study33, and “a positive trend in the incidence of renal tubule carcinoma and of renal tubule adenoma and carcinoma (combined)” in male CD-1 mice in a different two-year diet study34, with IARC noting that these malignant kidney tumors are rare in this strain of mice.

In contrast to the commenters implication that IARC only evaluated a select few studies in its monograph on glyphosate, IARC35 discussed each of the 14 sets of animal cancer

---

31 Section 25703(a)(4)
33 As noted in the Initial Statement of Reasons, this study of glyphosate (purity 98.6%) met the criterion in Section 25703 as the most sensitive study of sufficient quality, and was used to derive the NSRL. This study was performed by Inveresk Research International and summarized in the 2006 Joint FAO/WHO Meeting on Pesticide Residues report (JMPR, 2006. Glyphosate. In: Joint FAO/WHO Meeting on Pesticide Residues. Pesticide residues in food – 2004: toxicological evaluations. Report No. WHO/PCS/06.1. Geneva: World Health Organization; pp. 95 – 169.) and by IARC (IARC, 2015, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 112. Some Organophosphate Insecticides and Herbicides: Diazinon, Glyphosate, Malathion, Parathion, and Tetrachlorvinphos. IARC, World Health Organization, Lyon, France).
35 IARC (2015). Full citation provided in footnote 3
studies (five in mice and nine in rats)\textsuperscript{36} included in the review by Greim \textit{et al.} (2015)\textsuperscript{37}, as well as two additional sets of studies in rats, for a total of 16 sets of animal cancer studies. IARC noted in particular that the information reported in the article by Greim \textit{et al.} and provided in the supplemental materials lacked sufficient detail regarding “statistical methods, choice of doses, body-weight gain, survival data, details of histopathological examination, and/or stability of dosed feed mixture” to be evaluated\textsuperscript{38}. IARC evaluations “rely only on data that are in the public domain and available for independent scientific review”\textsuperscript{39}. Utilizing additional sources in the public domain, IARC was able to conduct independent scientific review of two of the five sets of mouse studies included in Greim \textit{et al.}, five of the nine sets of rat studies included in Greim \textit{et al.}, and two additional sets of rat studies not included in Greim \textit{et al.}.

OEHHA is not aware of any additional animal cancer studies of glyphosate, other than the 16 sets of studies discussed by IARC. Of those 16 sets, IARC found that two sets of studies in mice and six sets of studies in rats were \textit{adequate} for the evaluation of glyphosate carcinogenicity (emphasis added).

Of those eight sets of rodent studies, treatment-related increases in the incidence of malignant tumors were observed in one study in male mice, and treatment-related increases in the incidence of combined malignant and benign tumors were observed in a second male mouse study. Treatment-related increases in benign tumors were observed in two male rat studies and one female rat study; in each case, IARC noted there was no apparent progression of the benign tumors to malignancy.

Thus, OEHHA reviewed the available data from the rodent carcinogenicity studies of glyphosate in light of the requirement of Section 25703 that the assessment “be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”, and determined that the two-year study conducted in male CD-1 mice fed glyphosate (purity, 98.6\%) in the diet met the criterion in Section 25703 as the most sensitive study of sufficient quality. OEHHA agrees with IARC’s determination that the increased incidence of hemangiosarcomas observed in this study of male CD-1 mice is treatment-related.

\textsuperscript{36} Each set of studies consists of two experiments, one in males and one in females.
\textsuperscript{38} IARC (2015). Full citation provided in footnote 3.
OEHHA used this data to derive the NSRL for glyphosate. OEHHA did not rely on US EPA’s conclusions to derive the NSRL for glyphosate; nor did OEHHA rely on Monsanto’s scientific opinions to derive the NSRL (see also Response #3).

No changes were made to the regulatory proposal based on this comment.

**Comment 6 (Valerie Noble and several commenters):** The proposed NSRL does not account for bioaccumulation of glyphosate. Food Democracy Now further stated that a 2004 joint report from the United Nations Food and Agriculture [Organization] Program [*sic*] and the World Health Organization determined that glyphosate accumulates in the bones of lab animals.

**Response 6:** Valerie Noble did not provide a citation for the finding she attributed to Kruger et al. regarding bioaccumulation of glyphosate. OEHHA performed a literature search and identified one publication authored by Monika Kruger40. Contrary to the commenter’s assertion, this publication provides no data indicating that glyphosate bioaccumulates. OEHHA is not aware of any evidence from studies in humans that demonstrate that glyphosate bioaccumulates. Similarly, there is no evidence that glyphosate bioaccumulates in non-human primates, or other mammals. For example, in rhesus monkeys, nearly all of an intravenous dose of glyphosate was eliminated within 24 hours41, and in Fischer 344 rats greater than 90% of an oral dose of glyphosate was eliminated within 72 hours42. In another rat study, the total body burden of radiolabeled glyphosate residues measured 7 days after a single oral dose was approximately 1% of the administered dose. Further, no evidence of glyphosate bioaccumulation was observed in two repeated dosing studies conducted in rats43.

The report referred to by the commenters appears to be the 2006 Joint FAO/WHO Meeting on Pesticide Residues (JMPR) report. However, the report does not conclude that glyphosate accumulates in the bones of lab animals. The report states that, after reviewing studies in mammals, there is no evidence of accumulation of glyphosate in

---

mammals. No changes were made to the regulatory proposal based on this comment.

**Comment 7 (Meghan Lawler, Pesticide Free Zone, and Laura Hayes, Linda Causey, Zen Honeycutt and other commenters):** OEHHA should consider effects other than carcinogenicity in setting the NSRL, such as evidence of induction of liver disease at 4 nanograms/kg, teratogenicity, breakdown of the blood-brain barrier, and evidence of destruction of gut bacteria at 0.1 ppm. Meghan Lawler and Laura Hayes stated that glyphosate is a neurotoxin, endocrine disruptor, mineral chelator, and antibiotic, and that it causes liver disease.

Some commenters stated that the NSRL fails to account for the potential transgenerational effects of endocrine disruptors, and asserted that an appropriate study to determine the NSRL should involve mice studies for three generations. Pesticide Free Zone commented that by excluding low dose studies from consideration, OEHHA may not be accounting for harmful endocrine-disrupting chemical actions. Laura Hayes commented that the most serious negative health consequences result when glyphosate substitutes for glycine during protein synthesis.

**Response 7:** Proposition 65 requires the maintenance and updating of a list of chemicals that cause cancer or reproductive toxicity, and requires businesses that knowingly cause exposures to listed chemicals to provide warnings. Other health effects – including liver disease, breakdown of the blood-brain barrier and destruction of gut bacteria – are outside the scope of the law. Following the guidance set forth in Section 25703, OEHHA bases NSRLs on cancer dose-response assessments, which are conducted using data from the most sensitive scientific studies deemed to be of sufficient quality. Observations of liver disease, teratogenicity, breakdown of the blood-brain barrier, destruction of gut bacteria, and endocrine disruption are not observations of cancer, and thus studies relating to such health effects do not provide data that can be used in a cancer dose-response assessment. The NSRL for glyphosate is based on animal carcinogenicity studies, and dose-response analysis of tumor incidence data from these studies.

---


In reviewing the mechanistic data available for glyphosate, IARC did not conclude that glyphosate is carcinogenic via endocrine disruption. Rather, IARC concluded that there was strong evidence for genotoxicity and oxidative stress, and weak evidence for receptor-mediated effects. There are no data to suggest that glyphosate acts as a carcinogen via a transgenerational mechanism. OEHHA is not aware of any multi-generational cancer studies of glyphosate.

No changes were made to the regulatory proposal based on these comments.

**Comment 8 (K. Paul Stoller, MD, Nancy O'Mara, MPH, Mei-Ling Stefan, Anthony Samsel and others):** Urge consideration of the possible human health effects of other chemicals present in commercial formulations of glyphosate, e.g. adjuvants, surfactants, and inert ingredients, as well as consideration of possible synergism of glyphosate with other xenobiotic chemicals. There are no safe levels of the N-nitrosamines of glyphosate that are found in every glyphosate product.

**Response 8:** The Proposition 65 warning requirement applies only to chemicals listed for causing cancer or reproductive toxicity. In this case, the substance listed as causing cancer is glyphosate\(^\text{46}\), not commercial formulations of glyphosate. Analysis of possible effects (e.g., additive, synergistic, or antagonistic) of other exposures that may co-occur with glyphosate is outside the scope of Proposition 65 and is not relevant to the derivation of the NSRL for glyphosate. Thus, the NSRL is based on the results of the most sensitive scientific study of *glyphosate* deemed to be of sufficient quality. No changes were made to the regulatory proposal based on this comment.

**Comment 9 (Dr. Stephen C. Frantz, Nancy O'Mara, MPH, and others):** Urge consideration of a non-linear dose-response relationship, stating that endocrine disrupting chemicals, such as glyphosate, do not demonstrate the common default monotonic dose-response relationship.

**Response 9:** No data were provided to support the assertions that a non-monotonic cancer dose-response relationship exists for glyphosate.

---

\(^{46}\) As noted in the Notice of Intent to List Glyphosate ([https://oehha.ca.gov/proposition-65/cmrnotice-intent-list-tetrachlorvinphos-parathion-malathion-glyphosate](https://oehha.ca.gov/proposition-65/cmrnotice-intent-list-tetrachlorvinphos-parathion-malathion-glyphosate)) and the Notice of Listing ([https://oehha.ca.gov/proposition-65/cmrnotice/glyphosate-listed-effective-july-7-2017-known-state-california-cause-cancer](https://oehha.ca.gov/proposition-65/cmrnotice/glyphosate-listed-effective-july-7-2017-known-state-california-cause-cancer)), the 2015 IARC monograph on glyphosate indicates the following chemicals are “also relevant: 38641-94-0 (glyphosate-isopropylamine salt) 40465-66-5 (monoammonium salt) 69254-40-6 (diammonium salt) 34494-03-6 (glyphosate-sodium) 81591-81-3 (glyphosate-trimesium)” (IARC, 2015b), because these salts dissociate to free glyphosate.
As discussed in the Initial Statement of Reasons (ISOR)\(^47\) for this action, OEHHA reviewed the available data from the rodent carcinogenicity studies of glyphosate discussed by IARC and determined that the most sensitive scientific study of sufficient quality for the cancer dose-response assessment was a study in male mice in which a statistically significant increasing trend in hemangiosarcoma was observed. The data from this study exhibited a monotonic dose-response relationship. Based upon consideration of the available mechanistic and other relevant data, OEHHA fit a multistage polynomial cancer model to the dose-response data to estimate cancer potency and derive the NSRL for glyphosate. This is consistent with the guidance set forth in Section 25703. No changes were made to the regulatory proposal based on this comment.

**Comment 10 (Anthony Samsel):** Glyphosate is a synthetic amino acid and an analogue of glycine. Glyphosate ligates with lysozyme, which may impact fibrocystic cytokines and human and animal immune systems. Glyphosate inhibits several enzymes, including protease, lipase, and pepsins, which can have effects on human health.

The commenter submitted three publications that were not included in IARC’s review (Table 1).

**Response 10:** This comment is essentially a summary of Samsel and Seneff's 2016 article, entitled "Glyphosate pathways to modern disease V: Amino acid analogue of glycine in diverse proteins"\(^48\). This paper proposes a number of hypotheses regarding possible mechanisms by which glyphosate may effect human health. However, these hypotheses are not supported by experimental data and the relevance of the hypothesized health effects to cancer induction is unclear.

OEHHA reviewed each of the three publications in the context of the guidance set forth in Section 25703, which provides that “the assessment shall be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”\(^49\) and determined that none of the studies provide data that would affect the cancer dose-response analysis (See Table 1). No changes were made to the regulation based on this comment.

---


\(^{49}\) Section 25703(a)(4)
<table>
<thead>
<tr>
<th>Reference</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samsel A and Seneff S (2015). Glyphosate pathways to modern disease IV: Cancer and related pathologies. <em>Journal of Biological Physics and Chemistry</em> <strong>15</strong>:121-159.</td>
<td>This article reviews epidemiological evidence of cancers in humans exposed to glyphosate and mechanistic information on glyphosate, and discusses possible carcinogenic mechanisms. “Glyphosate has a large number of tumorigenic effects on biological systems, including direct damage to DNA in sensitive cells, disruption of glycine homeostasis, succinate dehydrogenase inhibition, chelation of manganese, modification to more carcinogenic molecules such as N-nitrosoglyphosate and glyoxylate, disruption of fructose metabolism, etc.”</td>
</tr>
<tr>
<td>Samsel A and Seneff S (2016). Glyphosate pathways to modern disease V: Amino acid analogue of glycine in diverse proteins. <em>Journal of Biological Physics and Chemistry</em> <strong>16</strong>:9-46.</td>
<td>This article proposes that glyphosate is a synthetic amino acid and analogue of glycine, which can be incorporated into peptides, affect various enzymes, and lead to numerous diseases. “Glyphosate, acting as a glycine analogue, may be mistakenly incorporated into peptides during protein synthesis.” “…the combination of activation of kinases and suppression of phosphatases that can plausibly be induced through glyphosate’s displacement of conserved glycines in the enzymes can be predicted to lead to an overabundance of phosphorylated molecules, systemically.” “Phosphorylation is a widespread modification with profound effects on affected molecules, which can increase risk to both Alzheimer’s disease and cancer.”</td>
</tr>
</tbody>
</table>
“VLA-4 [very late antigen-4] is required for normal development of both T- and B-cells in the bone marrow, in part by regulating the balance between proliferation and differentiation of haematopoietic progenitors [291]. It can therefore be expected that impaired function would lead to pathologies such as immune dysfunction and cancer. Two conserved glycine residues at positions 130 and 190 are essential for its adhesive activity [292]. Glyphosate's link to NHL may therefore be explained through substitution of glyphosate for glycine at one or both of these conserved residues.”

This paper proposes a number of theories regarding disease mechanisms. However, these theories are not supported by experimental data. This article does not provide data that would affect the cancer dose-response analysis that forms the basis for the NSRL.


This article is a review of glyphosate and autism, multiple sclerosis, and other autoimmune disorders. The only reference to cancer is the reporting of a correlation between the incidence of thyroid cancer in the US and an increase in glyphosate usage on corn and soy crops. However, statistical correlations of cancer incidence with usage/exposure are not enough to presume causation.

This article does not provide data that would affect the cancer dose-response analysis that forms the basis for the NSRL.

**Comment 11 (Dr. Stephen C. Frantz):** “Developing an NSRL that relies on ‘acceptable calculated reference doses’ supplied by the USEPA and its international counterparts is generally troublesome. That is, the EU ‘standard’ for daily chronic exposure to [glyphosate] is 0.5 mg/kg body weight, a level that is 3.5 fold lower than the U.S. ‘standard’ of 1.75 mg/kg body weight. Obviously, both levels cannot be acceptable and safe; and the EU version is already less than half of the proposed 1.1 mg by OEHHA.”

**Response 11:** The NSRL for glyphosate does not rely on “acceptable calculated reference doses” or other values calculated by other agencies. Following the guidance
set forth in Section 25703, NSRLs are based on cancer dose-response assessments, which are conducted using data from the most sensitive scientific studies deemed to be of sufficient quality. As discussed in the ISOR for this rulemaking\textsuperscript{50}, OEHHA determined that the two-year study conducted in male CD-1 mice fed glyphosate (purity, 98.6\%) in the diet met this criterion. OEHHA used this data to derive the NSRL for glyphosate.

Furthermore, as stated in Section 25703, an NSRL is defined as “[the level] which is calculated to result in one excess case of cancer in an exposed population of 100,000, assuming lifetime exposure at the level in question.” NSRLs are intended to aid businesses in determining if they must comply with the warning and discharge provisions of Proposition 65; NRSLs are not intended to establish exposure or risk levels for other regulatory purposes (Section 25701(d)).

While reference doses set by other agencies are not relevant to this rulemaking, OEHHA notes that the European Union has set the acceptable daily intake (ADI) for glyphosate at 0.5 mg/kg\textsuperscript{51}, and US EPA has set the chronic reference dose (cRfD) for glyphosate at 1.00 mg/kg-day\textsuperscript{52}; each of these values was developed by applying an uncertainty factor to a No Observed Adverse Effect Level (NOAEL) derived from developmental toxicity studies in rabbits. Neither value was based on cancer dose-response assessment and neither was developed specifically to protect against cancer. And finally, the ADI set by the European Union is not less than half of the proposed NSRL for glyphosate. The NSRL is expressed as an intake of µg/day, while the ADI (and cRfD) are expressed as mg/kg-day. Normalized to body weight, the NSRL would be less than the ADI or cRfD, not greater. No changes were made to the regulatory proposal based on this comment.

**Comment 12 (The California League of Food Processors):** Establishing an NSRL conflicts with tolerances set by US EPA for residues in food.

---


\textsuperscript{52} The commenter refers to the former cRfD set by US EPA. The value has been updated since the comment was submitted, as shown in US EPA (2017). Glyphosate. Dietary Exposure Analysis in Support of Registration Review. Office of Chemical Safety and Pollution Prevention. Available from: https://www.epa.gov/sites/production/files/2017-12/documents/glyphosate_diary_exposure_analysis_in_support_of_registration_review.pdf
Response 12: There is no direct correlation between a tolerance level set by US EPA and an NSRL adopted for purposes of Proposition 65. The two standards are developed under different laws and have different purposes. Whereas tolerances are mandatory maximum allowable pesticide residues on foods, NSRLs identify levels of exposure to listed carcinogens associated with a 1 in 100,000 cancer risk. If a food exposure to a pesticide listed as a carcinogen results in a cancer risk greater than 1 in 100,000, Proposition 65 requires a warning even if the food complies with US EPA’s tolerances and can be legally sold in California. In such an instance, Proposition 65 gives Californians the right to be informed of the exposure and to make their own decision as to whether they wish to purchase or consume the food. No changes were made to the regulatory proposal based on this comment.

Comment 13 (K. Paul Stoller, MD): Regulators should not rely on just one study to determine acceptable daily intake.

Response 13: No Significant Risk Levels (NSRLs) are distinct from Acceptable Daily Intakes (ADIs). The NSRL is defined in the Proposition 65 regulations as “[the level] which is calculated to result in one excess case of cancer in an exposed population of 100,000, assuming lifetime exposure at the level in question.” ADI values, on the other hand, are based on non-cancer health effects, and are neither defined nor used under Proposition 65.

In developing the NSRL for glyphosate, OEHHA followed the guidance set forth in Section 25703 and based the NSRL on the results of the most sensitive scientific study deemed to be of sufficient quality. No changes were made to the regulatory proposal based on this comment.

Comment 14 (Anthony Samsel): A thorough consideration cannot be had without a deep investigation and understanding of the nitrosamines of glyphosate which are carcinogens.

Response 14: Nitrosamines of glyphosate are not listed under Proposition 65 as causing cancer, nor are they the subject of this rulemaking. As discussed in response to comment 8, an NSRL applies specifically to the particular substance or chemical that has been listed as known to the state to cause cancer. Therefore, studies of other chemicals, such as nitrosamines of glyphosate, do not provide information relevant to the derivation of the NSRL for glyphosate. No changes were made to the regulatory proposal based on this comment.

53 Health and Safety Code section 25249.10(c) and Title 27, Cal. Code of Regs. section 25701.
Comment 15 (Ramboll Environ, on behalf of The Scotts Company, LLC): OEHHA and IARC failed to consider additional conclusions from the 2006 JMPR report on the study used to derive the NSRL, namely the lack of a dose-response relationship, the lack of statistically significant comparisons between treated animals and control animals, and the fact that the incidences were within the historical ranges for controls, and thus improperly reached conclusions regarding use of this data. Dr. Thomas McDonald, a peer reviewer and member of the Carcinogen Identification Committee, also stated that the dataset selected as the basis for the NSRL does not appear to be well supported as a treatment-related effect.

Response 15: As discussed in response to comment 5, IARC conducted an independent scientific review of the two-year study conducted in male CD-1 mice fed glyphosate (purity, 98.6%) in the diet, which OEHHA used to derive the NSRL. IARC concluded that a treatment-related increase in hemangiosarcomas was observed in this study, with a statistically significant positive trend. The tumor incidence data and positive trend test results, shown in Table 1 of the ISOR54, demonstrate the dose-response relationship observed for hemangiosarcoma in this study.

While the pairwise comparison between the tumor incidence in animals in the high dose group and those in the control group did not rise to the p < 0.05 level of statistical significance, data from Charles River Laboratories indicate that hemangiosarcomas are infrequently observed in untreated male CD-1 mice, with a mean incidence of 1.13% (range 0% – 12.00%) reported in 200055, and 0.56% (range 0% - 4.55%) in 201056. More specifically, no hemangiosarcomas were observed in untreated controls in 38 of the 46 studies summarized in 200057, or in 13 of the 14 studies summarized in 201058.

While JMPR\textsuperscript{59} stated that the tumor “incidences recorded in this study fell within the historical ranges for controls”, OEHHA notes, “concurrent controls are considered the most relevant comparison group for evaluating potential exposure-related tumor effects”\textsuperscript{60}. In discussing the use of historical control data, IARC states “less weight is given to historical controls when they show a high degree of variability, and greater weight when they show little variability. It is generally not appropriate to discount a tumour response that is significantly increased compared with concurrent controls by arguing that it falls within the range of historical controls, particularly when historical controls show high between-study variability and are, thus, of little relevance to the current experiment”\textsuperscript{61}.

OEHHA agrees with IARC’s determination that the increased incidence of hemangiosarcomas observed in this study of male CD-1 mice is treatment-related.

No changes were made based on this comment.

\textbf{Comment 16: (Ramboll Environ, on behalf of The Scotts Company, LLC):} The data used to derive the NSRL does not establish consistency across studies that is needed to provide a causal connection between exposure to glyphosate and cancer: there was no dose-related incidence of hemangiosarcoma reported in the female mouse study and no statistically significant increases in any tumors in another study with comparable concentrations.

\textbf{Response 16:} Section 25703(1) specifies that animal cancer bioassays must meet generally accepted scientific principles (e.g., the thoroughness of experimental protocol, the degree to which dosing resembles the expected manner of human exposure, the temporal exposure pattern, the duration of study, the purity of test material, the number and size of exposed groups, the route of exposure, and the extent of tumor occurrence) in order to be used in the development of NSRLs. In carcinogenicity testing there is no requirement or expectation that the same tumors will be seen in male and female animals of the same species and strain. It is also recognized that differences in study design (e.g., doses tested; length of exposure; length of study) and implementation (e.g., test substance purity/composition/lot; animal strain/substrain/colony supplier of


origin; diet composition; laboratory site, other animal husbandry conditions) may result in differences in response across animal carcinogenicity studies. Thus, consistency across animal studies is not required to establish a causal connection.

IARC concluded "[t]here is sufficient evidence in experimental animals for the carcinogenicity of glyphosate" based on findings from two studies in male mice. Specifically, IARC found "a significant positive trend in the incidence of haemangiosarcoma in male CD-1 mice" in a two-year diet study, and "a positive trend in the incidence of renal tubule carcinoma and of renal tubule adenoma and carcinoma (combined)" in male CD-1 mice in a different two-year diet study, with IARC noting that these malignant kidney tumors are rare in this strain of mice. Thus, IARC found dose-related increases in tumor incidence in these studies and OEHHA agrees with this determination.

In developing the NSRL for glyphosate, OEHHA followed the guidance set forth in Section 25703 and based the NSRL on the results of the most sensitive scientific study deemed to be of sufficient quality. No changes were made to the regulation based on this comment.

Comment 17 (Ramboll Environ, on behalf of The Scotts Company, LLC):
"Conducting dose-response modeling with a limited dataset – such as the dataset used in the derivation of the NSRL for glyphosate, which provides the observation of incidence above zero only at the highest concentration – creates significant model uncertainty." They also state that "this type of dataset lacks the necessary information to inform the shape of the dose-response curve in the low concentration region, which is needed for extrapolation to concentrations relevant to the human population and thus to estimate the NSRL."

Response 17: The proposed NSRL for glyphosate is based on the results of the most sensitive scientific study deemed to be of sufficient quality from which an NSRL can be derived, pursuant to Section 25703. Use of the multistage cancer model is generally

---

accepted as the default approach to modeling lifetime cancer data as it is considered sufficiently flexible to fit most cancer bioassay data\textsuperscript{64}. As stated in the ISOR for glyphosate\textsuperscript{65}, OEHHA determined that the study it used to derive the NSRL demonstrated a treatment-related increase in hemangiosarcomas, with a statistically significant positive trend. OEHHA disagrees with the commenter that modeling this data using the multistage cancer model “creates significant model uncertainty”; in fact, examination of the goodness-of-fit criteria\textsuperscript{66,67} subsequent to fitting the model supports the appropriateness of the default approach. In particular, the global goodness-of-fit p-value is 0.9365, which is well above the cutoff of 0.05, the scaled residuals are all less than two in absolute value, and the plot shows that the multistage cancer model fits the data very well. The relatively low incidence of hemangiosarcoma in the high dose group (8\%) effectively limits the possibilities the shape of the curve fit to the data can take. In fitting the multistage cancer model to this data, OEHHA followed the guidance in Section 25703, which is consistent with scientific practices in other OEHHA programs\textsuperscript{68} and other scientific guidance, including US EPA’s 2005 cancer risk assessment guidelines\textsuperscript{69}. No changes were made to the proposed regulation based on this comment.

**Comment 18 (Baum, Hedlund, Aristei & Goldman, P.C.):** Section 25703(a)(1) requires that OEHHA consider the “degree to which dosing resembles the expected manner of human exposure” and “the route of exposure.” The dietary ingestion of glyphosate as evaluated in the animal cancer bioassay considered by OEHHA does not resemble the expected manner of human exposure through application.

**Response 18:** The commenter has quoted only a portion of Section 25703(a)(1); OEHHA provides the full statement from the regulations for context and clarity:


“Animal bioassay studies for quantitative risk assessment shall meet generally accepted scientific principles, including the thoroughness of experimental protocol, the degree to which dosing resembles the expected manner of human exposure, the temporal exposure pattern, the duration of study, the purity of test material, the number and size of exposed groups, the route of exposure, and the extent of tumor occurrence.”

As can be seen in the full quotation of Section 25703(a)(1) above, “the degree to which dosing resembles the expected manner of human exposure” is one of several key considerations in determining whether or not an animal cancer bioassay is suitable for use in the development of an NSRL. OEHHA found the data used to derive the NSRL for glyphosate to be sufficient with respect to each of these considerations. With regard to the manner in which animals were dosed, diet is one of the expected routes of glyphosate exposure in humans and thus deriving the NSRL from study data in which test animals were administered glyphosate through the diet is consistent with the regulations. Animal bioassays employing dietary exposure are commonly used and routinely accepted for toxicity testing of pesticides.

**Comment 19 (Dr. Thomas McDonald):** OEHHA should make its own determination on the genotoxicity of glyphosate and not rely on IARC. He states that other authoritative bodies have concluded that glyphosate poses no genotoxicity risk in mammals, and that a Margin of Exposure (MOE) approach [to dose-response assessment] appears more appropriate.

**Response 19:** To the extent that the comment is directed toward the listing of glyphosate, it is not relevant to the determination of an NSRL for this chemical. OEHHA has reviewed the discussion of the mechanistic data for glyphosate provided in the IARC monograph and agrees with IARC’s conclusion that “Overall, the mechanistic data provide strong evidence for genotoxicity and oxidative stress. There is evidence that these effects can operate in humans.”

OEHHA notes that IARC further elaborated on this evidence, stating:

- “There is strong evidence that exposure to glyphosate or glyphosate-based formulations is genotoxic based on studies in humans in vitro and studies in experimental animals. One study in several communities in individuals exposed to glyphosate-based formulations also found chromosomal damage in blood cells; in this study, markers of chromosomal damage (micronucleus formation)

---

were significantly greater after exposure than before exposure in the same individuals."

- “There is strong evidence that glyphosate, glyphosate-based formulations, and aminomethylphosphonic acid can act to induce oxidative stress based on studies in experimental animals, and in studies in humans in vitro. This mechanism has been challenged experimentally by administering antioxidants, which abrogated the effects of glyphosate on oxidative stress. Studies in aquatic species provide additional evidence for glyphosate-induced oxidative stress.”

OEHHA disagrees that a Margin of Exposure approach is more scientifically appropriate for derivation of the NSRL for glyphosate than the procedure used by OEHHA. Section 25703 sets forth a default approach, using a multistage model for deriving a cancer potency estimate, which is used “in the absence of principles or assumptions scientifically more appropriate”\(^\text{72}\). No information has been provided in support of another mechanism of action that would suggest a different approach to dose-response analysis.

In deriving the NSRL, OEHHA used the Benchmark Dose (BMD) method, as described both in OEHHA’s guidance\(^\text{73}\) and in the US EPA guidelines\(^\text{74}\), applying a multistage mathematical model to describe the relationship between the risk of cancer and the dose. As part of the procedure OEHHA used for determining the cancer potency using the BMD method, a determination is made as to the proper type of extrapolation from the point of departure (typically the 95\% lower confidence limit of the ED\textsubscript{05} or ED\textsubscript{10} for tumor induction) to low doses. OEHHA considered whether there was a more scientifically appropriate method for the NSRL derivation than linear extrapolation, but did not identify one, stating in the Initial Statement of Reasons:

“Based on consideration of the available mechanistic information on glyphosate and the above conclusions reached by IARC\(^\text{75}\), a multistage model is applied to derive a cancer potency estimate, following the guidance in Section 25703. There are no principles or assumptions scientifically more appropriate, based on the available data, than this approach.”\(^\text{76}\)

---

\(^{72}\) Section 25703(a)


\(^{75}\) IARC (2015). Full citation provided in footnote 3.

No changes were made to the regulatory proposal based on this comment.

**Comment 20 (Food Democracy Now, The Agricultural Council of California, The California Farm Bureau Federation, Monsanto, Ramboll Environ on behalf of The Scotts Company LLC, Anthony Samsel, Jessica Denning, and PT Rothschild):**

Suggest alternative values for the NSRL for glyphosate:

Anthony Samsel, Frank Menhams and others commented that a value of 0 µg/day should be used because there is no safe level of glyphosate.

PT Rothschild recommended setting an NSRL based on a concentration of 0.01 parts per trillion.

Jessica Denning recommended setting an NSRL based on a concentration of 0.01 parts per trillion because at a part per trillion, breast cell proliferation occurs.

Food Democracy Now suggested 0.1 µg/day.

The Agricultural Council of California and the California Farm Bureau Federation request that the proposed NSRL [1,100 µg/day] be considered a minimum value and that no consideration be given to anything lower.

Monsanto states that glyphosate does not cause cancer, therefore, exposure at any level poses no significant risk of cancer to humans, therefore the NSRL should be infinite.

Ramboll Environ on behalf of The Scotts Company LLC, states that if OEHHA insists on setting an NSRL for glyphosate, it should be infinite.

**Response 20:** Section 25703 of the regulations states that the assessment used to derive the NSRL “shall be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”\(^77\). Section 25703 further states that “risk analysis shall be based on the most sensitive study deemed to be of sufficient quality.” No data that met these criteria were provided to support setting the NSRL at 0 or 0.1 µg/day, or setting an NSLR based on a concentration of 0.01 parts per trillion or 10 parts per quadrillion, nor were such data provided to support setting an infinite NSRL.

\(^77\) Section 25703(a)(4)
In developing the NSRL for glyphosate, OEHHA followed the guidance set forth in Section 25703 and based the NSRL on the results of the most sensitive scientific study deemed to be of sufficient quality. OEHHA determined that the two-year study conducted in male CD-1 mice fed glyphosate (purity 98.6%) in the diet met the criteria in 25703 precisely because this study led to the highest cancer potency and subsequently the lowest NSRL among studies deemed to be of comparable scientific validity as those which formed the scientific basis for the listing of glyphosate. As already noted, OEHHA agrees with IARC’s determination that the increased incidence of hemangiosarcomas observed in this study of male CD-1 mice is treatment-related.

No changes were made to the regulatory proposal based on this comment.

Comment 21 (The Environmental Working Group): OEHHA should set the limit at 10 µg/day which factors in a tenfold safety factor to account for the increased vulnerability of children, a one-in-a-million cancer risk standard used for carcinogens in drinking water, and rounding.

The commenter states that including a tenfold safety factor in the development of the NSRL for glyphosate is supported by OEHHA’s 2009 report “In Utero and Early Life Susceptibility to Carcinogens”, NRC’s 1993 report “Pesticides in the Diets of Infants and Children”, NRC’s 2009 report “Science and Decisions” which advises public health agencies to include a factor of up to 25 to account for individual variation in susceptibility, and the 1996 Food Quality Protection Act which specifically required pesticide risk assessors to consider children’s susceptibility to pesticides using a tenfold safety factor.

The commenter also states that OEHHA should use the one-in-a-million standard applied for carcinogens in drinking water for setting the NSRL for all exposures.

Response 21: The Food Quality Protection Act (FQPA), a federal law, is separate and distinct from Proposition 65, a California state law. Moreover, these two laws were established for different purposes and have different regulations and requirements. In particular, the FQPA relates to the setting of safety standards for pesticide residues in food, while Proposition 65 requires businesses to provide a warning when they cause an exposure to a listed chemical unless they can show the exposure does not exceed the safe harbor level, and prohibits the discharge of listed chemicals to sources of drinking water. Proposition 65 warnings are not required and the discharge prohibition does not apply when exposures are at or below the safe harbor level.

The NSRL is defined as “[the level] which is calculated to result in one excess case of cancer in an exposed population of 100,000, assuming lifetime exposure at the level in
question”\textsuperscript{78}. Thus, OEHHA cannot use a one-in-a-million level of risk in setting the NSRL. Similarly, OEHHA cannot apply a tenfold safety factor to the NSRL. The NSRL for glyphosate was derived according to the requirements set forth in Section 25703.

NSRLs do not conflict with permissible levels set by the federal government or with the one-in-a-million cancer risk standard for carcinogens in drinking water. These other laws have no bearing on Proposition 65, and it has no bearing on them. No changes to the regulatory proposal were made based on this comment.

**Comment 22 (Food Democracy Now!, Joanie Blaxter):** OEHHA should wait to consider a high NSRL for glyphosate until the studies showing carcinogenic effects in human populations can be replicated and extended. Joanie Blaxter commented that the testing model should be replaced with a more real life model of the effects of sub-acute low-level exposure over long periods of time in combination with exposure to other potentially activating chemicals and heavy metals.

**Response 22:** As stated in the response to Comment 1, glyphosate was listed pursuant to the Labor Code listing mechanism\textsuperscript{79} as a result of IARC’s classification of glyphosate in Group 2A (“probably carcinogenic to humans”), with a finding of “sufficient evidence of carcinogenicity in experimental animals” and “limited evidence” in humans\textsuperscript{80,81}. Section 25703 of the regulations states that the assessment used to derive the NSRL “shall be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”\textsuperscript{82}. Given that the listing of glyphosate is based on sufficient evidence in animals, basing the potency estimate for the NSRL on animal studies is both appropriate and consistent with Section 25703. It is not appropriate for OEHHA to wait for additional studies to be conducted in humans, or otherwise delay the adoption of the NSRL for glyphosate, which is intended to aid businesses in complying with Proposition 65. Should additional scientific studies become available in the future that meet the criteria set out in Section 25703, OEHHA can consider revising the NSRL for glyphosate at that time. No changes were made to the regulatory proposal based on this comment.

**Comment 23 (Comments from Food Democracy Now):** “A two year study on rats published in 2015 found that just 0.05 ppb changed the function of more than 4000 genes. It would behoove the commission to pay attention to any and all studies which

---

\textsuperscript{78} Section 24703.

\textsuperscript{79} Section 25249.8(a) of the Act


\textsuperscript{81} IARC (2015). Full citation provided in footnote 3.

\textsuperscript{82} Section 25703(a)(4)
suggest adverse human health effects at such miniscule levels. The study found steatohepatosis which predisposes to liver cancer at a glyphosate equivalent dose of only 4 nanograms per kg per day. The amount of glyphosate ingested by these rats is approximately 4000 times lower than what is typically ingested based on levels found in urine. This is the only study of its type providing a direct causative link between an environmentally relevant dose of Roundup and a serious disease.”

Response 23: The commenter appears to be referring to a 2015 publication by Mesnage et al.,83 that analyzed differences in gene expression, not gene function, in the liver and kidney of female rats administered a glyphosate-based herbicide in drinking water for two years, as compared with controls receiving “plain water”. Changes in gene expression levels were observed for more than 4000 genes in the liver and kidney of treated animals, as compared with controls. Treatment-related tumors were not reported in this study. This study does not provide data that would affect the cancer dose-response analysis that forms the basis for the NSRL. No changes were made to the regulatory proposal based on this comment.

Comment 24 (A number of commenters, including Meghan Lawler): Raised concerns about exposure to glyphosate, whether through food, consumer products, the environment, or during application as a pesticide. Some state that the proposed NSRL does not reflect real-world exposure scenarios or expected exposure concentrations. Some state that it is unclear how the increased exposure of agricultural workers will be factored in, when setting an NSRL. Some have reported various levels that a typical adult is exposed to on a daily basis. Some state that there is no way to establish or enforce a safe level because it is impossible to quantify cumulative exposure. Meghan Lawler commented that no comprehensive, long term, independent study has been done that shows real life exposure levels for glyphosate.

Response 24: Following the guidance set forth in Section 25703, NSRLs are based on cancer dose-response assessments, which are conducted using tumor incidence data from the most sensitive scientific studies deemed to be of sufficient quality. Cancer dose-response assessments are performed to estimate a carcinogen’s cancer potency, and the NSRL is derived based on the cancer potency estimate. Specifically, the NSRL is defined as “[the level] which is calculated to result in one excess case of cancer in an exposed population of 100,000, assuming lifetime exposure at the level in question”84. Thus, the NSRL is a level of exposure or intake, expressed in units of µg/day that is associated with a risk of cancer of one-in-100,000.

84 Section 24703.
Exposure information (e.g., exposure routes, exposure levels) is not used in dose-response assessment. Rather, estimates of exposure may be used together with estimates of cancer potency to predict cancer risk within a population.

As noted in response to comment 1, the estimate of cancer potency for glyphosate is equally valid for estimating risks to agricultural workers and to other exposed individuals, and the NSRL for glyphosate is not limited to a specific route of exposure.85,86

Many conventional regulatory standards are developed using the kind of real-world exposure information cited by the commenters. Those standards identify legally mandated, health-protective levels of exposures to chemicals that can be feasibly achieved by manufacturers and employers. The NSRL is not a conventional regulatory standard, as it is based strictly on the scientific criteria cited above. It is intended to guide businesses in determining whether a warning is necessary or whether discharges of a chemical into drinking water sources are prohibited. A Proposition 65 warning enables Californians to make informed choices about their exposures to listed chemicals.

Comment 25 (Several commenters): The proposed level is too high, and one commenter stated that, in comparison, the NSRL for TCDD is much lower.

Response 25: The comment compares the proposed NSRL for glyphosate, 1100 µg/day, to the NSRL for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), which is 0.000005 µg/day. It has long been recognized that carcinogens vary in strength, or potency, with some being extremely potent, and others much less potent. Indeed, the cancer potencies of carcinogens vary by several orders of magnitude. NSRLs, which are derived from cancer potency estimates, can similarly vary by orders of magnitude, as can be seen when comparing the NSRL for glyphosate to that for TCDD. Thus, the fact that the NSRL for glyphosate is much higher than the NSRL for TCDD is not an indication that the glyphosate NSRL is too high, or otherwise inappropriate.

In developing the NSRL for glyphosate, OEHHA followed the guidance set forth in Section 25703 and based the NSRL on the results of the most sensitive scientific study deemed to be of sufficient quality. OEHHA determined that the two-year study

86 Section 25703(a)(4)
88 Ibid.
conducted in male CD-1 mice fed glyphosate (purity 98.6%) in the diet met the criteria in 25703 precisely because this study led to the highest cancer potency and subsequently the lowest NSRL among studies deemed to be of comparable scientific validity as those which formed the scientific basis for the listing of glyphosate. As already noted, OEHHA agrees with IARC’s determination that the increased incidence of hemangiosarcomas observed in this study of male CD-1 mice is treatment-related. No changes were made based on this comment.

Comment 26 (Laura Hayes, Pesticide Free Zone and Tamsin Lisa Kelly, JD, MD): The proposed level is a random rate that cannot be accurately monitored or enforced. Pesticide Free Zone asked how OEHHA would determine the amount that humans are exposed to on a daily basis. Tamsin Lisa Kelly, JD, MD, stated that if use is allowed, testing of food and water supplies must be required regularly to assure exposure is limited.

Response 26: OEHHA disagrees with the statement that the proposed NSRL for glyphosate is a random rate. As described in more detail in Response 19 OEHHA followed standard cancer dose-response assessment practice in deriving an NSRL of 1100 µg/day for glyphosate, which is based on the most sensitive study of sufficient quality. OEHHA’s approach is consistent with Section 25703, scientific practices in other OEHHA programs89 and other scientific guidance, including US EPA’s 2005 cancer risk assessment guidelines90.

OEHHA has no authority under Proposition 65 to monitor exposures to listed chemicals. Businesses are responsible for determining if they are causing exposures to listed chemicals at levels that require warnings. The purpose of the NSRL is to assist businesses in making these determinations. Similarly, OEHHA has no authority under Proposition 65 to require testing of food and water supplies. No changes were made to the regulatory proposal based on this comment.

Comment 27 (A Voice for Choice, Organic Sacramento, and several others): The NSRL does not account for differences in vulnerability due to size, age, stage of development, health status, or socioeconomic status.

Response 27: As specified in Section 25703, the “risk analysis shall be based on the most sensitive study deemed to be of sufficient quality”, and “the risk level which represents no significant risk shall be one which is calculated to result in one excess

case of cancer in an exposed population of 100,000, **assuming lifetime exposure at the level in question**”. (Emphasis added)

In developing the NSRL for glyphosate, OEHHA followed the guidance set forth in Section 25703 and based the NSRL on the results of the most sensitive scientific study deemed to be of sufficient quality. The calculation assumes lifetime exposure at the level in question to an average person in the general population. No changes were made to the regulation based on this comment.

**Comment 28 (A number of commenters):** Urge OEHHA to ban glyphosate, that it be declared a “restricted use” chemical, that it not be available to the public, or that OEHHA should ensure labeling of all products, businesses, and public spaces containing any amount of glyphosate. Bob Sanders commented that instead of considering an NSRL, OEHHA should be discussing glyphosate as “not safe for human consumption” (NSFHC) and including 10 mile safety zones to protect children and families.

**Response 28:** Proposition 65 does not give OEHHA authority to remove products or chemicals from the market or to restrict their use. While OEHHA has regulatory authority to broadly identify acceptable methods and content for Proposition 65 warnings, OEHHA does not have the authority to directly regulate product labeling as suggested by the commenters. Similarly, Proposition 65 does not give OEHHA the authority to categorize glyphosate as not safe for human consumption or to impose safety zones as suggested by the commenter. These comments are outside the scope of the current rulemaking and no changes were made based on this comment.

**Comment 29 (Larry Wartels, Susan and others):** OEHHA should use the precautionary principle in developing the NSRL for glyphosate. OEHHA should only allow use of the lowest effective levels of glyphosate so that plants do not become glyphosate resistant.

**Response 29:** In developing the NSRL for glyphosate, OEHHA followed the guidance set forth in Section 25703 of the regulations, which states that the assessment used to derive the NSRL “shall be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”. Glyphosate was listed pursuant to the Labor Code listing mechanism as a result of IARC’s classification of glyphosate in Group 2A (“probably carcinogenic to humans”), with a finding of sufficient evidence of

---

91 The commenter did not provide a last name.
92 Section 25703(a)(4)
93 Section 25249.8(a) of the Act
carcinogenicity in experimental animals\textsuperscript{94,95}. OEHHA reviewed the available data from the rodent carcinogenicity studies of glyphosate discussed by IARC\textsuperscript{96}, and determined that the two-year study conducted in male CD-1 mice fed glyphosate (purity, 98.6\%) in the diet met the criterion in Section 25703 as the most sensitive study of sufficient quality. OEHHA agrees with IARC’s determination that the increased incidence of hemangiosarcomas observed in this study of male CD-1 mice is treatment-related. OEHHA then performed a standard dose-response assessment using the data from this study to derive the NSRL for glyphosate. The resistance of plants to glyphosate is not relevant for purposes of deriving an NSRL. No changes were made based on this comment.

**Comment 30 (One commenter (anonymous)):** Extrapolating cancer risk to humans from hemangiosarcomas, which are very rare in humans, seems misleading and to use this to determine the NSRL seems unscientific.

**Response 30:** The premise underlying this comment is incorrect. It is a generally accepted principle that the ability of a chemical to cause cancer in animals is predictive that the chemical also poses a cancer hazard in humans\textsuperscript{97}. However, it is not assumed that the same tumor type observed in animals will be observed in humans\textsuperscript{98}. Similarly, the fact that cancer potency is estimated based on animal tumor data for a particular tumor type does not imply that the cancer potency applies specifically to that same tumor type in humans. The human cancer potency estimate is a measure of the carcinogenic hazard posed by a particular carcinogen, and can be used to estimate the risk of cancer (at all sites that may be affected by this carcinogen) associated with a specific level of exposure in humans. No changes were made in response to this comment.

**Comment 31 (Baum, Hedlund, Aristei & Goldman, P.C., Meredith Newton, Timothy Litzenburg and others):** Raised concerns over OEHHA meeting with representatives from Monsanto in October 2015. The commenters state that OEHHA should be presented with an impartial and comprehensive scope of data in determining the NSRL and that industry meetings with regulators should be open to public scrutiny. Timothy


\textsuperscript{95} IARC (2015). Full citation provided in footnote 3.

\textsuperscript{96} IARC (2015). Full citation provided in footnote 3.


Litzenburg requested that OEHHA schedule a meeting with stakeholders before making a decision on the safe harbor threshold.

Response 31: This comment is not directed towards the rulemaking. In compliance with the Administrative Procedure Act (APA), OEHHA published a Notice of Proposed Rulemaking, thereby opening a 45-day public comment period, and held a public hearing where all interested parties were allowed to provide their input regarding the proposed rulemaking. OEHHA provided the public with the opportunity to provide written comments during the comment period. OEHHA is publicly responding to all the oral and written comments received during the rulemaking in this Final Statement of Reasons. Nothing in the APA prohibits OEHHA from meeting with stakeholders to hear all viewpoints on an issue. The October 2015 meeting occurred before glyphosate was added to the Proposition 65 list of chemicals and before the current rulemaking proposal. OEHHA also met with many of the commenters, including representatives of Baum, Hedlund, Aristei & Goldman, P.C. and Timothy Litzenburg and others in August 2017 to understand their position concerning the NSRL. No changes were made to the proposed regulation based of this comment.

Comment 32 (Zen Honeycutt): Section 25703 requires OEHHA to consider all available studies showing harm. Provided many references for OEHHA’s consideration, many of which were not included in IARC’s review (Table 2.)

Response 32: Section 25703 does not mandate a review of all available studies showing harm. Rather Section 25703 requires that the assessment “be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”, and the NSRL must be based on the results of the most sensitive scientific study deemed to be of sufficient quality.

Of the 72 published scientific articles listed in the comments from Zen Honeycutt, 54 were not cited in the IARC Monograph that OEHHA relied on in developing the NSRL for glyphosate. These 54 publications are listed in Table 2. OEHHA reviewed each of these publications in the context of the guidance set forth in Section 25703, i.e., “the assessment shall be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer” and determined that none of the studies provide data that would affect the cancer dose-response analysis (See Table 2). No changes were made to the regulatory proposal based on this comment.

---

100 Section 25703(a)(4)
Table 2. Studies related to glyphosate that were identified by Zen Honeycutt and not considered by IARC

<table>
<thead>
<tr>
<th>Reference</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astiz M, Alaniz MJT de, Marra CA (2009). The impact of simultaneous intoxication with agrochemicals on the antioxidant defense system in rat. <em>Pesticide Biochemistry and Physiology</em> <strong>94</strong>:93-99.</td>
<td>This study in rats examined the effects of glyphosate on oxidative stress, and hormone levels. This mechanistic study does not provide data that would affect the cancer dose-response analysis that forms the basis for the NSRL.</td>
</tr>
<tr>
<td>Benedetti AL, Vituri Cde L, Trentin AG, Domingues MA, Alvarez-Silva M (2004). The effects of sub-chronic exposure of Wistar rats to the herbicide Glyphosate-Biocarb. <em>Toxicol Lett</em> <strong>153</strong>(2):227-32.</td>
<td>This study examined the effects of Glyphosate-Biocarb® on the livers of Wistar rats following 75 days of exposure. This subchronic toxicity study does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>Benedetti D, Nunes E, Sarmento M, Porto C, Dos Santos CE, Dias JF, da Silva J (2013). Genetic damage in soybean workers exposed to pesticides: evaluation with the comet</td>
<td>This study in farm workers assessed the effects of exposure to complex mixtures of pesticides, including glyphosate, on DNA. The authors reported that DNA damage and genomic hypermethylation of DNA were significantly increased in individuals exposed</td>
</tr>
<tr>
<td>Reference</td>
<td>Summary</td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>and buccal micronucleus cytome assays. <em>Mutat Res</em> <strong>752</strong>(1-2):28-33.</td>
<td>to pesticide mixtures, but it does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>Beuret CJ, Zirulnik F, Giménez MS (2005). Effect of the herbicide glyphosate on liver lipoperoxidation in pregnant rats and their fetuses. <em>Reprod Toxicol</em> <strong>19</strong>(4):501-4.</td>
<td>This study investigated the effects of glyphosate on pregnant female Wistar rats and their fetuses. This reproductive toxicity study provides no data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>Cox C (2004). Herbicide factsheet: glyphosate. <em>Journal of Pesticide Reform</em> <strong>24</strong>(4):10-15.</td>
<td>This factsheet is a short review and does not provide data that would affect the cancer dose-response analysis that forms the basis for the NSRL.</td>
</tr>
<tr>
<td>da Costa Mdo D, Gonçalves LR, Barbosa ER, Bacheschi LA (2003). Neuroimaging abnormalities in parkinsonism: study of five cases. <em>Arq Neuropsiquiatr</em> <strong>61</strong>(2B):381-6. [Article in Portuguese]</td>
<td>This study reports neuroimaging results in five patients with Parkinson’s disease, one of whom was exposed to glyphosate. This study is not relevant to cancer dose-response analysis.</td>
</tr>
<tr>
<td>Dallegave E, Mantese FD, Coelho RS, Pereira JD, Dalsenter PR, Langeloh A (2003). The teratogenic potential of the herbicide glyphosate-Roundup in Wistar rats. <em>Toxicol Lett</em> <strong>142</strong>(1-2):45-52.</td>
<td>This study examined the teratogenicity of glyphosate-Roundup® to Wistar rats. This developmental toxicity study provides no data relevant to cancer dose-response analysis.</td>
</tr>
<tr>
<td>de Liz Oliveira Cavalli VL, Cattani D, Heinz Rieg CE, Pierozan P, Zanatta L, Benedetti Parisotto E, Wilhelm</td>
<td>This study investigated the effects of glyphosate on male rat Sertoli cells and testis</td>
</tr>
<tr>
<td>Reference</td>
<td>Summary</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Geng D et al. (2000). Study of Herbicide Roundup impact on yellow eel</td>
<td>This study investigated the genotoxicity of glyphosate in the erythrocytes of <em>Monopterus albus</em> (Asian swamp eel) <em>in vivo</em>. It suggests that glyphosate induces chromosomal aberrations. While this study contributes to the data on possible mechanisms of action, it does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>Hokanson R, Fudge R, Chowdhary R, Busbee D (2007). Alteration of estrogen-regulated gene expression in human cells induced by the agricultural and horticultural herbicide glyphosate. <em>Hum Exp Toxicol</em> <strong>26</strong>:747-52.</td>
<td>This <em>in vitro</em> study investigated the effects of glyphosate on human MCF-7 cells and found altered gene expression. This mechanistic study does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>Jayawardena UA, Rajakaruna RS, Navaratne AN, Amerasinghe PH</td>
<td>This toxicity study of glyphosate and other pesticides observed malformations in exposed...</td>
</tr>
</tbody>
</table>

Tree frogs. This study provides no data relevant to cancer dose-response analysis.


This study on Parkinson’s disease is not relevant to cancer dose response-analysis.


The hyperlink provided by the commenter leads to an article by Kang et al. (2008), named “Study on mutagenesis induced by glyphosate in mice”. The full text also indicates that this study was in mice, but not rats. Other than the title, the rest of the citation is correct. This study reports that glyphosate induced micronucleus formation in bone marrow polychromatic erythrocytes of Kunming mice, increased sperm aberrations, and decreased sperm count.

While this study contributes to the data on possible mechanisms of action, it does not provide data that would affect the cancer dose-response analysis that forms the basis for the NSRL.


This study measured glyphosate residues in animals and humans using ELISA and gas chromatography-mass spectroscopy. Glyphosate residues were detected in the kidney, liver, lung, spleen, muscles, and intestine in dairy cows (minimum = 1.36 µg/g; maximum of 108 µg/mg). Glyphosate residues were detected in the urine of dairy cows (minimum = 0 µg/ml; maximum = 164...
<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-g/ml, rabbits (minimum = 2.37 μg/ml; maximum = 70 μg/ml) and humans (minimum = 0.1 μg/ml; maximum = 71.3 μg/ml). Significantly higher urinary glyphosate residues were reported in chronically ill humans than in healthy individuals. This study provides no data relevant to cancer dose response analysis.</td>
<td></td>
</tr>
<tr>
<td>Lajmanovich RC, Sandoval MT, Peltzer PM (2003). Induction of mortality and malformation in Scinax nasicus tadpoles exposed to glyphosate formulations. <em>Bull Env Contam Toxicol</em> 70:612–618.</td>
<td>This study investigated the effects of glyphosate on tadpoles exposed for 96 hours. This acute toxicity study in amphibians provides no data relevant to cancer dose-response analysis.</td>
</tr>
<tr>
<td>Lioi MB, Scarfi MR, Santoro A, Barbieri R, Zeni O, Salvemini F, Di Berardino D, Ursini MV (1998). Cytogenetic damage and induction of pro-oxidant state in human lymphocytes exposed in vitro to glyphosate, vinclozolin, atrazine, and DPXE9636. <em>Environ Mol Mutagen</em> 32(1):39-46.</td>
<td>This <em>in vitro</em> study in human peripheral lymphocytes reported that glyphosate exposure increased chromosomal aberrations, sister chromatid exchanges, and a change in the redox state of the cell. This study contributes to the data on possible mechanisms of action, but it does not provide data that would affect the cancer dose-response analysis that forms the basis for the NSRL.</td>
</tr>
<tr>
<td>Marc J, Mulner-Lorillon O, Boulben S, Hureau D, Durand G, Bellé R (2002). Pesticide Roundup provokes cell division dysfunction at the level of CDK1/cyclin B activation. <em>Chem Res Toxicol</em> 15(3):326-31.</td>
<td>This study investigated the effects of Roundup® and glyphosate on cell cycle regulation in sea urchin embryos. This mechanistic study does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>Reference</td>
<td>Summary/Comment</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Formulated glyphosate activates the DNA-response checkpoint of the cell</td>
<td>This mechanistic study does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>cycle leading to the prevention of G2/M transition. <em>Toxicol Sci</em></td>
<td></td>
</tr>
<tr>
<td><strong>82</strong>(2):436-42.</td>
<td></td>
</tr>
<tr>
<td>Marc J, Mulner-Lorillon O, Bellé R (2004b). Glyphosate-based pesticides</td>
<td>This paper investigated the effects of several glyphosate-based pesticides on cell cycle regulation in sea urchins.</td>
</tr>
<tr>
<td>affect cell cycle regulation. <em>Biol Cell</em> 96**(3)**:245-9.</td>
<td>This mechanistic study does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>Marc J, Le Breton M, Cormier P, Morales J, Bellé R, Mulner-Lorillon O</td>
<td>This study investigated the effects of glyphosate on sea urchin development and found effects on transcription in early development. This study does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>McComb BC, Curtis L, Chambers CL, Newton M, Bentson K (2008). Acute toxic</td>
<td>This study evaluated the effects of acute exposure to glyphosate on white lab mice and 9 wild vertebrate species from the Oregon coast (deer mouse, chipmunk, shrew, vole, newt, frog, and three types of salamanders). This acute toxicity study does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>hazard evaluations of glyphosate herbicide on terrestrial vertebrates of</td>
<td></td>
</tr>
<tr>
<td>Mesnage R, Clair E, Spiroux de Vendômois J, Séràlìni GE (2010). Two</td>
<td>This is a report of two instances of congenital malformations in children whose parents had been exposed to multiple pesticides, including glyphosate. These case reports are not relevant to cancer dose-response analysis.</td>
</tr>
<tr>
<td>cases of birth defects overlapping Stratton-Parker syndrome after multiple</td>
<td></td>
</tr>
<tr>
<td>Mesnage R, Renney G, Seralini GE, Ward M (2017) Multiomics reveal non-</td>
<td>This study used metabolome and proteome analyses of rat liver tissue to investigate the effects of low-dose exposure of rats to a glyphosate-based herbicide. The authors concluded that the metabolome and proteome changes observed were indicative of non-alcoholic fatty liver disease. This study does</td>
</tr>
<tr>
<td>alcoholic fatty liver disease in rats following chronic exposure to an</td>
<td></td>
</tr>
</tbody>
</table>
null
<table>
<thead>
<tr>
<th>Authors</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oliveira AG, Telles LF, Hess RA, Mahecha GA, Oliveira CA (2007). Effects of the herbicide Roundup on the epididymal region of drakes Anas platyrhynchos. <em>Reprod Toxicol</em> <strong>23</strong>(2):182-91.</td>
<td>This study investigated the effects of Roundup® on the epididymis and testes of adult male ducks exposed for 15 days. This male reproductive toxicity study provides no data relevant to cancer dose-response analysis.</td>
</tr>
<tr>
<td>Perkins PJ, Boermans HJ, Stephenson GR (2000). Toxicity of glyphosate and triclopyr using the frog embryo teratogenesis assay—Xenopus. <em>Environmental Toxicology and Chemistry</em> <strong>19</strong>: 940–945.</td>
<td>The effects of glyphosate were studied on the embryonic development of <em>Xenopus laevis</em>. This developmental toxicity study is not relevant to cancer dose-response analysis.</td>
</tr>
<tr>
<td>Relyea RA (2012). New effects of Roundup on amphibians: predators reduce herbicide mortality; herbicides induce antipredator morphology. <em>Ecol Appl</em> <strong>22</strong>(2):634-47.</td>
<td>This study examined the effects of Roundup on the response of amphibians to predators. This behavioral study is not relevant to cancer dose-response analysis.</td>
</tr>
<tr>
<td>Romano RM, Romano MA, Bernardi MM, Furtado PV, Oliveira CA (2010). Prepubertal exposure to commercial formulation of the herbicide glyphosate alters testosterone levels and testicular morphology. <em>Arch Toxicol</em> <strong>84</strong>(4):309-17.</td>
<td>This paper reports the effects of glyphosate on testicular development in male rats exposed on postnatal days 23 to 53. This study does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>Roy NM, Ochs J, Zambrzycka E, Anderson A (2016). Glyphosate induces cardiovascular toxicity in Danio rerio. <em>Environmental Toxicology and Pharmacology</em></td>
<td>This study investigated the effects of glyphosate on heart development in zebrafish. This developmental toxicity study is not relevant to cancer dose-response analysis.</td>
</tr>
</tbody>
</table>

This human epidemiology study assessed pesticide exposure, including exposure to glyphosate, on male reproductive outcomes. This male reproductive toxicity study is not relevant to cancer dose-response analysis.


This study examined the effects of glyphosate on the Jundia fish and found effects on reproductive status. This fish reproductive toxicity study does not provide data that can be used in the cancer dose-response analysis.


This study provides no data specific to glyphosate.


This study examined the effects of glyphosate on the development of turtle eggs. This developmental toxicity study in turtles is not relevant to cancer dose-response analysis.


This descriptive study conducted correlation analyses based on time trends in genetically engineered crop data, glyphosate application data, and disease rates in the US. A significant correlation was reported between glyphosate application rates and incidence of thyroid, liver, bladder, pancreas, and kidney cancer, and myeloid leukemia. Incidences of these cancers were also correlated with percentages of genetically engineered corn and soy planted in the US.
This descriptive study provides correlations between glyphosate usage and disease rates. However, a descriptive study does not provide evidence of causation. Additionally, there is a latency period between exposure to a carcinogen and development of cancer. In this study, however, there was often a temporal overlap between increases in glyphosate use and increases in cancer incidence (e.g., no evidence of latency between exposure and cancer). In some cases, cancer incidences increased before glyphosate use did.

Descriptive studies such as this do not provide data that can be used in cancer dose-response analysis.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wu H (1996). Glyphosate impact on rat cytochrome P450 2 B1 and P450 2 c11 gene expression. Health</td>
<td>The hyperlink provided by the commenter leads to an article by Wu and Prough (1996), titled “CYP450 2B1 and 2C11 expression in</td>
</tr>
<tr>
<td>Reference</td>
<td>Summary</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><em>Toxicology Journal, 10</em>(4): 231-234 [Article in Chinese] Available from <a href="http://www.cnki.com.cn/Article/CJFDTotal-WSDL604.004.htm">http://www.cnki.com.cn/Article/CJFDTotal-WSDL604.004.htm</a></td>
<td>&quot;Rat by glyphosate&quot;. Other than the different title, the rest of the citation is correct. This study examined liver microsomal enzyme activity as well as expression levels of CYP450 2B1 and 2C11 mRNA in rats after glyphosate treatment by oral gavage. This study does not provide data that can be used in the cancer dose-response analysis.</td>
</tr>
<tr>
<td>Zeng M, Huang T et al. (2014). Glyphosate toxicity to mice GC-1 sperm cells and the interference effect of N-acetyl cysteine, <em>Ecological Toxicology Bulletin</em> 1. [Article in Chinese] Available from <a href="http://www.cnki.com.cn/Article/CJFDTotal-STDL201401031.htm">http://www.cnki.com.cn/Article/CJFDTotal-STDL201401031.htm</a></td>
<td>The hyperlink provided by the commenter leads to an article by Zeng et al. (2014), titled &quot;Cytotoxicity of Glyphosate to GC-1 Mice Spermatogonium and Antagonistic Effects of N-acetyl cysteine&quot;. Other than the title, the rest of the citation is correct. This study examined the cytotoxicity of glyphosate on GC-1 (mouse spermatogonia) cells. The study found that glyphosate induced DNA damage as shown by the Comet assay, and suggests that glyphosate may increase reactive oxygen species production in GC-1 cells. While this study contributes to the data on possible mechanisms of action, it does not provide data that would affect the cancer dose-response analysis that forms the basis for the NSRL.</td>
</tr>
<tr>
<td>Zhao W et al. (2011). Study of oxidative damage of the body</td>
<td>This study examined oxidative damage induced by glyphosate in Kunming mice.</td>
</tr>
</tbody>
</table>

Oxidative damage was measured as levels of total antioxidant capacity (TAC) and malondialdehyde (MDA) in serum and several tissues, and as serum levels of advanced oxidation products. While this study contributes to the data on possible mechanisms of action, it does not provide data that would affect the cancer dose-response analysis that forms the basis for the NSRL.


This *in vitro* study investigated the effects of glyphosate on cultured mouse Sertoli cells. This male reproductive toxicity study does not provide data that can be used in the cancer dose-response analysis.

**Comment 33:** Teri Persico, Sandy DeSimone, William Brooks, Dr. Stephanie Seneff, and a number of other commenters provided lists of references for OEHHA’s consideration.

**Response 33:** Of the published scientific articles listed in these comments, OEHHA carefully reviewed each of the cited documents in the context of the guidance set forth in Section 25703, in the same manner as was done in response to comment 32 above. Specifically the regulations states that “the assessment shall be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”.\(^{101}\) OEHHA determined that none of the cited studies provide data that would affect the cancer dose-response analysis\(^{102}\). No changes were made to the regulatory proposal based on these comments.

**Comment 34 (Baum, Hedlund, Aristei and Goldman, P.C.):** “Additional documents pertinent to the Safe Harbor NSRL and Roundup/glyphosate carcinogenicity are presently still under seal and it is strongly recommended that OEHHA obtain access to

---

\(^{101}\) Section 25703(a)(4)

\(^{102}\) In fact, most of the articles were unrelated to carcinogenicity and instead focused on topics such as ecotoxicity, environmental fate and transport, analytical methods, mechanisms unrelated to carcinogenicity, and more.
such documents before OEHHA takes the potentially precarious step of issuing an NSRL of 1100 micrograms.”

**Response 34:** OEHHA used publicly available scientific studies to calculate the NSRL. There is no legal basis for OEHHA to ask a court in a third party matter to provide it with sealed documents. In the event these materials become publicly available in the future and they are relevant to the calculation of the NSRL, OEHHA can reconsider the NSRL at that time. No changes were made to the regulatory proposal based on this comment.

**Comment 35:** Carcinogen Identification Committee members Dr. Jason Bush, Dr. Luoping Zhang, and Dr. Shanaz Dairkee had no objections to the proposed NSRL. Colton Bond commented that the NSRL is a reasonably conservative benchmark. Chris Portier supported use of the multistage model and the extrapolation plan for the evaluation of glyphosate carcinogenicity. Anne Surdzial recommended that OEHHA adopt the NSRL as is, which is supported by science.

**Response 35:** No response is required. No changes were made to the regulatory proposal based on this comment.

**Comment 36 (Linda Causey):** Request determination on the economic cost to finding glyphosate in California wines.

**Response 36:** This comment is not related to the rulemaking. An NSRL does not require a business to test for the presence of glyphosate in California wines or any other products. In the Economic Impact Analysis for this rulemaking, OEHHA noted:

“One year after the date of listing, businesses that manufacture, distribute or sell products with glyphosate in the state must provide a warning if their product or activity exposes the public or employees to significant amounts of this chemical. *The regulatory proposal does not create additional compliance requirements, but instead provides a “safe harbor” value that aids businesses in determining whether a warning is required for a given exposure.* (Emphasis added.)

Benefits of this regulation include sparing businesses the expense of calculating their own NSRL and possibly enabling them to reduce or avoid litigation costs…”

No changes were made based on this comment.

**Comment #37 (Timothy Litzenburg):** The single mouse study that OEHHA relied on was done by a glyphosate producer.

**Response #37:** Studies conducted or contracted by the chemical manufacturer often form part of the scientific data supporting carcinogenicity. As noted in the response to
comment #5, IARC found that two sets of studies in mice and six sets of studies in rats were adequate for the evaluation of glyphosate carcinogenicity. OEHHA reviewed the available data from the rodent carcinogenicity studies of glyphosate in light of the requirement of Section 25703 that the assessment “be based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of the chemical as known to the state to cause cancer”, and determined that the two-year study conducted in male CD-1 mice fed glyphosate (purity, 98.6%) in the diet met the criterion in Section 25703 as the most sensitive study of sufficient quality. No changes were made based on this comment.

**Local Mandate Determination**

OEHHA has determined this regulatory action will not impose a mandate on local agencies or school districts nor does it require reimbursement by the State pursuant to Part 7 (commencing with Section 17500) of Division 4 of the Government Code. Local agencies and school districts are exempt from Proposition 65. OEHHA has also determined that no nondiscretionary costs or savings to local agencies or school districts will result from this regulatory action. The regulation does not create additional compliance requirements, but instead provides a “safe harbor” value that aids businesses in determining whether a warning is required for a given exposure.

**Alternatives Determination**

Pursuant to Government Code section 11346.5(a)(13), OEHHA initially determined that no reasonable alternative considered by OEHHA, or that has otherwise been identified and brought to the attention of OEHHA, would be more effective in carrying out the purpose for which the action is proposed, or would be as effective and less burdensome to affected private persons than the proposed action, or would be more cost-effective to affected private persons and equally effective in implementing the statutory policy or other provision of law.

In accordance with Government Code section 11346.9(a)(4), OEHHA has considered available alternatives to determine whether any alternative would be more effective in carrying out the purpose for which the regulations were proposed. OEHHA has also considered whether an alternative exists which would be as effective as and less burdensome to affected private persons than the proposed action. OEHHA has determined that no alternative considered would be more effective, or as effective as and less burdensome to affected private persons than the proposed regulation. No alternative that is less burdensome yet equally as effective in achieving the purposes of the regulation in a manner that achieves the purposes of the statute has been proposed. The NSRL provides a “safe harbor” value that aids businesses in determining if they are complying with the law. The regulation does not create additional compliance requirements, but instead provides a “safe harbor” value that aids
businesses in determining whether a warning is required for a given exposure. The alternative to the proposed amendment to Section 25705(b) would be to not adopt an NSRL for the chemical. Failure to adopt an NSRL would leave the business community without a “safe harbor” level to assist businesses in complying with Proposition 65. Some commenters proposed alternative NSRLs and approaches for deriving an NSRL. These comments were not reasonable alternatives and are fully discussed in responses to comments within this FSOR. There were no small-business specific alternatives submitted during the rulemaking process.